

**Group Art Unit: 1646** 

Re Application of:

Chen W. Liaw, et al.

Serial No.: 10/083,168

Filing Date: February 26, 2002

**Examiner: Not Yet Assigned** 

ENDOGENOUS AND NON-ENDOGENOUS VERSIONS OF HUMAN G For:

PROTEIN-COUPLED RECEPTORS

COPY OF PAPERS **ORIGINALLY FILED**  DATE OF DEPOSIT:

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE ASSISTANT COMMISSIONER FOR PATENTS,

Gwilym J.O. Attwell STRATION NO.: 45,449

**Assistant Commissioner for Patents** Washington, D.C. 20231

Dear Sir:

 $\boxtimes$ 

3

#### INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

> In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first office action after the filing of request for continued examination under §1.114, no additional fee is required.

DOCKET NO	0.: ARI	EN-032	0	- 2 -		PATENT
	In acc	ordance	e with §1.129(a	n), this Inform	nation Disclosure	Statement is being
	filed in connection with $\square$ the first or $\square$ second After Final Submission,					
	therefo	ore:				
		Certifi	cation in Acco	rdance with §	1.97(e) is attache	d; or
		The fe	e of <b>\$180.00</b> as	s set forth in §	31.17(p) is attache	ed.
	In acco	ordance	with §1.97(c),	this Informati	on Disclosure Sta	tement is being filed
	after th	ne perio	d set forth in §	1.97(b) above	but before the m	ailing date of either
	a Final	Action	under §1.113 c	or a Notice of	Allowance under	§1.311, or before an
	action	that oth	nerwise closes p	prosecution in	the application,	therefore:
			Certification i	n Accordance	e with §1.97(e) is	attached; or
			The fee of \$13	80.00 as set fo	orth in §1.17(p) is	attached.
	In acco	ordance	with §1.97(d),	this Informati	on Disclosure Sta	tement is being filed
	after t	he mail	ling date of eit	ther a Final A	Action under §1.	113 or a Notice of
	Allow	ance un	der §1.311 but	before, or sim	ultaneously with	, the payment of the
	Issue F	Fee, the	refore included	are: Certificat	tion in Accordanc	e with §1.97(e); and
	the sub	omissio	n fee of <b>\$180.0</b>	0 as set forth	in §1.17(p).	
	Copies	s of eac	ch of the refere	ences listed o	on the attached F	orm PTO-1449 are
	enclos	ed here	with.			
	Copies	of refe	rences listed on	the attached F	Form PTO-1449 a	re enclosed herewith
	EXCE	PT TH	AT:			
		In viev	w of the voluming	nous nature of	freferences [list a	s appropriate], and
		the lik	elihood that the	ese references	are available to the	he Examiner, copies
		are no	t enclosed here	with.		

- In accordance with §1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C.§120 have been made in the instant application:
- Copies of references **AA thru HS** listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. **09/170,496**, filed **October 13, 1998**.
  - ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

There are no listed references which are not in the English language.

Date: May 21. 2002

Gwilym J.O. Attwell Registration No. 45,449

WOODCOCK WASHBURN LLP

One Liberty Place - 46th Floor

Philadelphia, PA 19103 Telephone: (215) 568-3100 Facsimile: (215) 568-3439

3

© 2001 WW



10

COPY OF PAPERS ORIGINALEY FILED

Ş

\$ 60 m

ij



# RECEIVED JUN 0 5 2002 TECH CENTER 1600/2900 f 18

	The same of the sa	<u> </u>	40EMARIT	
Forn	n PTO-1449 Modified	•	Docket No. AREN-0320	Serial No. 10/083,168
	of Patent and Publications Cited by Applicant several sheets if necessary)		Applicant Chen W. Liaw et al	
	Department of Commerce nt and Trademark Office	Filing Date February 26, 2002	Group 1646	
ОТН	ER DOCUMENTS (Including	Autho	r, Title, Date, Pertine	nt Pages, Etc.)
AA	Alla, S.A. et al., "Extracellula ligand binding and agonist ser 1996, 271, 1748-1755	r doma nsing de	ins of the bradykinin Befined by anti-peptide	22 receptor involved in antibodies," J. Biol. Chem.,
AB	and selective nonpeptide antag	Advenier, C. et al., "Effects on the isolated human bronchus of SR 48968, a potent and selective nonpeptide antagonist of the neurokinin A (NK <sub>2</sub> ) receptors," Am. Rev. Respir. Dis., 1992, 146(5, Pt. 1), 1177-1181		
AC	Alexander, W.S. et al., "Point mutations within the dimer interfact homology domain of c-Mpl induce constitutive receptor activity and tumorigenicity," <i>EMBO J.</i> , <b>1995</b> , 14(22), 5569-5578			
AD	Arvanitikis, L. et al., "Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation," <i>Nature</i> , 1997, 385, 347-349			
AE	Barker, E.L. et al., "Constitutively active 5-hydroxytryptamine <sub>2C</sub> receptors reveal novel inverse agonist activity of receptor ligands," <i>J. Biol. Chem.</i> , <b>1994</b> , <i>269</i> (16), 11687-11690			
AF	Baxter, G., "5-HT <sub>2</sub> receptors: a family re-united?" Trends Pharmacol. Sci., 1995, 16, 105-110			
AG	Besmer, P. et al., "A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family," Nature, 1986, 320, 415			
АН	Blin, N. et al., "Mapping of single amino acid residues required for selective activation of G <sub>q/11</sub> by the m3 muscarinic acetylcholine receptor," <i>J. Biol. Chem.</i> , 1995, 270, 17741-17748			
AI	Bond, R.A. et al., "Inverse agonists and G-protein-coupled receptors," in <i>Receptor-Based Drug Design</i> , Leff, P. (ed.), New York, M. Dekker, <b>1998</b> , 363-377			
AJ	Boone, C. et al., "Mutations that alter the third cytoplasmic loop of the a-factor receptor lead to a constitutive and hypersensitive phenotype," <i>Proc. Natl. Acad. Sci. USA</i> , 1993, 90(21), 9921-9925			
EXAMINER			DATE CONSIDERE	SD .



1.5

**EXAMINER** 

MAY 2 9 2002

## RECEIVED

JUN 0 5 2002

'	K 23	TFC	H CENTER 1600 1290 2 of 18	
Form	PTO Modified	TEC Procket No. AREN-0320	Serial No. 10/083,168	
	Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Chen W. Liaw et al.		
	Pepartment of Commerce t and Trademark Office	Filing Date February 26, 2002	Group 1646	
ОТНЕ	R DOCUMENTS (Including Author	or, Title, Date, Pertine	nt Pages, Etc.)	
AK	Burstein, E.S. et al., "Constitutive a and delineation of G-protein couplin 1996, 51(4), 539-544			
AL		Burstein, E.S. et al., "Amino acid side chains that define muscarinic receptor/G-protein coupling. Studies of the third intracellular loop," J. Biol. Chem., 1996, 271(6), 2882-2885		
AM	Burstein, E.S. et al., "Constitutive activation of muscarinic receptors by the G-protein $G_{q}$ ," FEBS Lett., 1995, 363(3), 261-263			
AN	Bylund, D., "International union of pharmacology nomenclature of adrenoceptors," <i>Pharmacol. Rev.</i> , <b>1994</b> , <i>46</i> , 121-136			
AO	Casey, C. et al., "Constitutively active mutant 5-HT <sub>2A</sub> serotonin receptors: inverse agonist activity of classical 5HT <sub>2A</sub> antagonists," Soc. Neurosci., 1996, Abstract #699.10			
AP	Cheatham, B. et al., "Substitution of the <i>erbB-2</i> oncoprotein transmembrane domain activates the insulin receptor and modulates the action of insulin-receptor substrate 1," <i>Proc. Natl. Acad. Sci. USA</i> , <b>1993</b> , <i>90</i> , 7336-7340			
AQ	Chen, J. et al., "Tethered Ligand Library for Discovery of Peptide Agonists," J. Biol. Chem., 1995, 270, 23398-23401			
AR	Chen, T.S. et al., "Microbial hydroxylation and glucuronidation of the angiotensin II (AII) receptor antagonist MK 954," <i>J. Antibiot. (Tokyo)</i> , <b>1993</b> , <i>46(1)</i> , 131-134			
AS	Chen, W. et al., "A colorimetric assay for measuring activation of G <sub>s</sub> - and G <sub>q</sub> -coupled signaling pathways," <i>Anal. Biochem.</i> , <b>1995</b> , 226(2), 349-354			
AT	Chidiac, P. et al., "Inverse agonist a Exp. Ther., 1994, 45, 490-499	ctivity of β-adrenergic a	antagonists," J. Pharm.	
AU	Clozel, M. et al., "In vivo pharmacon nonpeptide endothelin receptor anta Cardiovas. Pharmacol., 1993, 22(S	gonist: implications for		

DATE CONSIDERED



MAY 2 9 2002

#### **RECEIVED**

JUN 0 5 2002

TECH CENTER-1600/290018

Form	PTO-1449 Modic	ed a de
	5-24	i i

Serial No. 10/083,168

List of Patent and Publications Cited by Applicant (Use several sheets if necessary) **Applicant** Chen W. Liaw et al.

U.S. Department of Commerce Patent and Trademark Office

Filing Date February 26, 2002 | 1646

Group

Pater	nt and Trademark Office	February 26, 2002	1646			
ОТН	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
AV	Collesi, C. et al., "A splicing variant of kinase activity and an invasive phenotype	_	<u> </u>			
AW	Cooper, C.S. et al., "Molecular cloning of a new transforming gene from a chemically transformed human cell line," <i>Nature</i> , <b>1984</b> , <i>311</i> , 29-33					
AX	De Dios, I. et al., "Effect of L-364,71 Pancreatic Secretion of Hydrocortison	•	•			
AY	Desbios-Mouthon, C. et al., "Deletion of $Asn^{281}$ in the $\alpha$ -subunit of the human insulin receptor causes constitutive activation of the receptor and insulin desensitization," <i>J. Clin. Endocrinol. Metab.</i> , <b>1996</b> , 81(2), 719-727					
AZ	· · · · · · · · · · · · · · · · · · ·	Di Renzo, M.F. et al., "Expression of the Met/HGF receptor in normal and neoplastic human tissues," <i>Oncogene</i> , 1991, 6(11), 1997-2003				
ВА	Di Renzo, M.F. et al., "Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas," Oncogene, 1992, 7, 2549-2553					
ВВ	Duprez, L. et al., "Germline mutations of the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperethyroidism," <i>Nature Genetics</i> , <b>1994</b> , <i>7</i> , 396-401					
ВС	Eggericksx, D. et al., "Molecular Cloning of an Orphan G-Protein-Coupled Receptor that Constitutively Activates Adenylate Cyclase," <i>Biochem. J.</i> , <b>1995</b> , <i>309</i> , 837-843					
BD	Evans, B.E. et al., "Orally Active, Nonpeptide Oxytocin Antagonists," J. Med. Chem., 1992, 35, 3919-3927					
ВЕ	Fu, M. et al., "Functional autoimmune epitope on α <sub>1</sub> -adrenergic receptors in patients with malignant hypertension," <i>Lancet</i> , <b>1994</b> , <i>344</i> , 1660-1663					
BF	Furitsu, T. et al., "Identification of Mutations in the Coding Sequence of the Proto- oncogene c-kit in a Human Mast Cell Leukemia Cell Line Causing Ligand- independent Activation of c-kit Product," J. Clin. Invest., 1993, 92, 1736-1744					
BG	Gellai, M. et al., "Nonpeptide Endoth Reversal of Acute Renal Failure in th 1995, 275(1), 200-206	-				
EXAMINER		DATE CONSIDERI	E <b>D</b>			

18



	MAY 2 8 MAY 2 9 2	<b>102</b> (5)	JUN 0 5 2002
	HAI 2 8 MILE	A TE	CH CENTER 168hppgropof 18
Form	PTO-144 Modified RADEMAN		Serial No.
	ADENT	AREN-0320	10/083,168
List of	Patent and Publications	Applicant	
	Cited by Applicant	Chen W. Liaw et al.	
(Use se	everal sheets if necessary)		
	Department of Commerce	Filing Date	Group
 Paten	t and Trademark Office	February 26, 2002	1646
ОТНЕ	R DOCUMENTS (Including Author	, Title, Date, Pertine	nt Pages, Etc.)
вн	Gitter, B. et al., "Pharmacological Characterization of LY303870: A Novel Potent and Selective Nonpeptide Substance P (Neurokinin-1) Receptor Antagonist," <i>J. Pharm. Exp. Therp.</i> , <b>1995</b> , <i>275</i> (2), 737-744		
BI	Gouilleux-Gruart, V. et al., "STAT-Related Transcription Factors are Constitutively Activated in Peripheral Blood Cells from Acute Leukemia Patients," <i>Blood</i> , <b>1996</b> , 87(5), 1692-1697		
BJ	Hansson, J.H. et al., "Hypertension caused by a truncated epithelial sodium channel γ subunit: genetic heterogeneity of Liddle syndrome," <i>Nat. Genet.</i> , <b>1995</b> , <i>11(1)</i> , 76-82		
BK	Hasegawa, H. et al., "Two Isoforms of the Prostaglandin E Receptor EP3 Subtype Different in Agonist-independent Constitutive Activity," J. Biol. Chem., 1996, 271(4), 1857-1860		
BL	Hendler, F. et al., "Human Squamous Cell Lung Cancers Express Increased Epidermal Growth Factor Receptors," J. Clin. Invest., 1984, 74, 647-651		
ВМ	Herrick-Davis, K. et al., "Constitutively Active 5HT2C Serotonin Receptor Created by Site-Directed Mutagenesis," Soc. Neurosci., Abstract No. 699.18		
BN	Hieble, J., "International union of pha nomenclature of 1-adrenoceptors," Ph	= -	

BO Hill, S., "Distribution, Properties, and Functional Characteristics of Three Classes of Histamine Receptor," Am. Soc. Pharm. Exp. Therap., 1990, 42(1), 45-83 BP Högger, P. et al., "Activating and Inactivating Mutations in - and C-terminal i3 Loop Junctions of Muscarinic Acetylcholine Hm1 Receptors," J. Biol. Chem., 1995, 270(13), 7405-7410 BQ Ikeda, H. et al., "Expression and Functional Role of the Proto-oncogene c-kit in Acute Myeloblastic Leukemia Cells," Blood, 1991, 78(11), 2962-2968 BR Imura, R. et al., "Inhibition by HS-142-1, a novel nonpeptide atrial natriuretic peptide antagonist of microbial origin, of atrial natriuretic peptide-induced relaxation of isolated rabbit aorta through the blockade of guanylyl cyclase-linked receptors," Mol. Pharm., 1992, 42, 982-990 **EXAMINER DATE CONSIDERED** 



**3**5

COPY OF PAPERS

E9846

## **RECEIVED**

JUN 0 5 2002

	The state of the s	<i>y</i>	JUN 0 3 2002 TECH CENTER 1609/2000
Form	Productied Rose	Docket No. AREN-0320	Serial No. 10/083,168
	f Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Chen W. Liaw et al	•
	Department of Commerce nt and Trademark Office	Filing Date February 26, 2002	Group 1646
ОТН	ER DOCUMENTS (Including Auth	or, Title, Date, Pertin	ent Pages, Etc.)
BS	Jakubik, J. et al., "Constitutive act receptors in transfected CHO cells revealed by negative antagonists,"	and of muscarinic rece	ptors in the heart cells
BT	Kjelsberg, M.A. et al., "Constituti amino acid substitutions at a single	ve activation of the α <sub>1B</sub> - e site," <i>J. Biol. Chem.</i> , 1	adrenergic receptor by all 1992, 267(3), 1430-1433
BU	Knapp, R. et al., "Molecular biology and pharmacology of cloned opioid receptors," <i>FASEB J.</i> , <b>1995</b> , <i>9</i> , 516-525		
BV	Kosugi, S. et al., "Characterization of heterogeneous mutations causing constitutive activation of the luteinizing hormone receptor in familial male precocious puberty," <i>Human Mol. Genetics</i> , <b>1995</b> , <i>4</i> (2), 183-188		
BW	Kosugi, S. et al., "Identification of Thyroid-Stimulating Antibody-Specific Interaction Sites in the N-Terminal Region of the Thyrotropin Receptor," <i>Mol. Endocrinology</i> , <b>1993</b> , <i>7</i> , 114-130		
BX	Kraus, M. et al., "Demonstration of ligand-dependent signaling by the <i>erbB-3</i> tyrosine kinase and its constitutive activation in human breast tumor cells," <i>Proc. Natl. Acad. Sci. USA</i> , 1993, 90, 2900-2904		
BY	Kudlacz, E. et al., "In Vitro and In Vivo Characterization of MDL 105,212A, a Nonpeptide NK-1/NK-2 Tachykinin Receptor Antagonist," J. Pharm. Exp. Therap., 1996, 277(2), 840-851		
BZ	Kuriu, A. et al., "Proliferation of Human Myeloid Leukemia Cell Line Associated with the Tyrosine-Phosphorylation and Activation of the Proto-oncogene c-kit Product," Blood, 1991, 78(11), 2834-2840		
CA	Labbé-Jullié, C. et al., "Effect of the nonpeptide neurotensin antagonist, SR 48692, and two enantiomeric analogs, SR 48527 and SR 49711, on neurotension binding and contractile responses in guinea pig ileum and colon," <i>J. Pharm. Exp. Therap.</i> , <b>1994</b> , <i>271</i> (1), 267-276		
СВ	Latronico, A. et al., "A novel mutation of the luteinizing hormone receptor gene causing male gonadotropin-independent precocious puberty," J. Clin. Endocrinol. Metabl., 1995, 80(8), 2490-2494		
XAMINER		DATE CONSIDERE	D





JUN 0 5 2002

TECH CENTER 1600 1999 6 of 18

Form PTO-Per Modified

Docket No.

AREN-0320

**Applicant** 

Serial No. 10/083,168

List of Patent and Publications Cited by Applicant (Use several sheets if necessary)

Chen W. Liaw et al.

U.S. Department of Commerce Patent and Trademark Office Filing Date

Group

February 26, 2002

1646

OT	THER	R DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
<del></del>		Laue, L. et al., "Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male-limited precocious puberty," <i>Proc. Natl. Acad. Sci USA</i> , <b>1995</b> , <i>92</i> , 1906-1910
C	CD	Løvlie, R. et al., "The Ca <sup>2+</sup> -sensing receptor gene (PCAR1) mutation T151M in isolated autosomal dominant hypoparathyroidism," <i>Hum. Genet</i> , <b>1996</b> , <i>98</i> , 129-133
C	CE	Lefkowitz, R. et al., "Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins," <i>Trends Pharmacol. Sci.</i> , <b>1993</b> , <i>14</i> , 300-307
C	CF	Libermann, T. et al., "Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin," <i>Nature</i> , <b>1985</b> , <i>313</i> , 144-147
C	CG	Liu, C. et al., "Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas," Oncogene, 1992, 7, 181-185
(	СН	Liu, J. et al., "Molecular mechanisms involved in muscarinic acetylcholine receptor-mediated G protein activation studied by insertion mutagenesis," <i>J. Biol. Chem.</i> , 1996, 271(11), 6172-6178
	CI	Lonardo, F. et al., "The normal <i>erbB-2</i> product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand," <i>New Biologist</i> , <b>1990</b> , 2(11), 992-1003
	CJ	Maenhaut, C. et al., "RDC8 codes for an adenosine A2 receptor with physiological constitutive activity," <i>Biochem. Biophys. Res. Comm.</i> , <b>1990</b> , <i>173</i> (3), 1169-1178
(	CK	Mann, J. et al., "Increased serotonin <sub>2</sub> and β-adrenergic receptor binding in the frontal cortices of suicide victims," <i>Arch. Gen. Psychiatry</i> , <b>1986</b> , 43, 954-959
	CL	Marone, R.L. et al., "Human CRF receptor chimeras: Mapping of ligand binding determinants," 26th Meeting of the Society of Neuroscience, Washington, D.C. November 16-21, <b>1996</b> , Abstract No. 609.8

EXAMINER

CM

DATE CONSIDERED

Magnusson, Y. et al., "Autoimmunity in idiopathic dilated cardiomyopathy,"

Circulation, 1994, 89, 2760-2767

iš.

1

COPY OF PAPERS

RECEIVED JUN 0 5 2002 TECH CENTER 1600/2900 Serial No. Form PTO Pt Docket No. 10/083,168 **AREN-0320** List of Patent and Publications Applicant Chen W. Liaw et al. Cited by Applican (Use several sheets if necessary) Group Filing Date U.S. Department of Commerce 1646 February 26, 2002 Patent and Trademark Office OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Matus-Leibovitch, N. et al., "Truncation of the thyrotropin-releasing hormone receptor **CN** carboxyl tail causes constitutive activity and leads to impaired responsiveness in Xenopus Oocytes and AtT20 Cells," J. Biol. Chem., 1995, 270(3), 1041-1047 Myles, G.M. et al., "Tyrosine 569 in the c-Fms juxtamembrane domain is essential for CO kinase activity and macrophage colony-stimulating factor-dependent internalization," Mol. Cell. Biol., 1994, 14(7), 4843-4854 Nanevicz, T. et al., "Thrombin receptor activating mutations," J. Biol. Chem., 1996, **CP** 271(2), 702-706 Natali, P.G. et al., "Expression of the c-Met/HGF receptor in human melanocytic CQ neoplasms: demonstration of the relationship to malignant melanoma tumour progression," Br. J. Cancer, 1993, 68, 746-750 Neilson, K.M. et al., "Constitutive activation of fibroblast growth factor receptor-2 by CR a point mutation associated with Crouzon syndrome," J. Biol. Chem., 1995, 270(44), 26037-26040 Oda, S. et al., "Pharmacological profile of HS-142-1, a novel nonpeptide atrial natriuretic CS peptide (ANP) antagonist of microbial origin. II. Restoration by HS-142-1 of ANP-induced inhibition of aldosterone production in adrenal glomerulosa cells," J. Pharm. Exp. Ther., 1992, 263(1), 241-245 O'Dowd, B.F. et al., "Site-directed mutagenesis of the cytoplasmic domains of the CT human β2-adrenergic receptor," J. Biol. Chem., 1988, 263(31), 15985-15992 Offermanns, S. et al., "G $\alpha_{15}$  and G $\alpha_{16}$  Couple a Wide Variety of Receptors to CU Phospholipase C," J. Biol. Chem., 1995, 270, 15175-15180 Palkowitz, A.D. et al., "Structural evolution and pharmacology of a novel series of CV triacid angiotensin II receptor antagonists," J. Med. Chem., 1994, 37, 4508-4521 Parent, J. et al., "Mutations of two adjacent amino acids generate inactive and **CW** constitutively active forms of the human platelet-activating factor receptor," J. Biol. Chem., 1996, 271(14), 7949-7955

Parfitt, A.M. et al., "Hypercalcemia due to constitutive activity of the parathyroid

DATE CONSIDERED

hormone (PTH)/PTH-related peptide receptor: comparison with primary


hyperparathyroidism," J. Clin. Endocr. Metabl., 1996, 81, 3584-3588

養

 $\mathbf{C}\mathbf{X}$ 

**EXAMINER** 

3



JUN 0 5 2002

**TECH CENTER 1600/2900** Sheet 8 of 18

	W.	6.	.637
Form	PTOM	A Q N	And ified
1 01 111	110-1		

List of Patent and Publications Cited by Applicant

AREN-0320

Serial No. 10/083,168

Applicant

Chen W. Liaw et al.

(Use s	several sheets if necessary)	Chen W. Liaw et al.			
•	Department of Commerce ont and Trademark Office	Filing Date February 26, 2002	Group 1646		
ОТН	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
СУ		Parma, J. et al., "Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas," <i>Nature</i> , <b>1993</b> , <i>365</i> , 649-651			
CZ	Pei, G. et al., "A constitutive active n desensitized and phosphorylated," Pr				
DA	basal acid secretion and prevents gastroi	Pendley, C.E. et al., "The gastrin/cholecystokinin-B receptor antagonist L-365,260 reduces basal acid secretion and prevents gastrointestinal damage induced by aspirin, ethanol and cysteamine in the rat," <i>J. Pharmacol. Exp. Ther.</i> , 1993, 265(3), 1348-1354			
DB		Peroutka, S., "Serotonin receptor subtypes. Their evolution and clinical relevance," CNS Drugs, 1995, 4 (Suppl. 1), 18-28			
DC	Pettibone, D.J. et al., "Development and pharmacological assessment of novel peptide and nonpeptide oxytocin antagonists," <i>Regul. Pept.</i> , <b>1993</b> , <i>45</i> , 289-293				
DD	Prat, M.P. et al., "The receptor encoded by the human c-Met oncogene is expressed in hepatocytes, epithelial cells and solid tumors," Int. J. Cancer, 1991, 49, 323-328				
DE	Prezeua, L. et al., "Changes in the carboxy-terminal domain of metabotropic glutamate receptor 1 by alternate splicing generate receptors with differing agonist-independent activity," <i>Mol. Pharmacol.</i> , <b>1996</b> , <i>49</i> , 422-429				
DF	Rakovska, A. et al., "Effect of loxiglumide (CR 1505) on CCK-induced contractions and <sup>3</sup> H-acetylcholine release from guinea-pig gallbaldder," <i>Neuropeptides</i> , <b>1993</b> , 25(5), 271-276				
DG	Ren, Q. et al., "Constitutive active mutants of the α <sub>2</sub> -adrenergic receptor," J. Biol. Chem., 1993, 268, 16483-16487				
DH	Reynolds, E.E. et al., "Pharmacological characterization of PD 156707, an orally active ET <sub>A</sub> receptor antagonist," <i>J. Pharmacol. Exp. Ther.</i> , <b>1995</b> , <i>273(3)</i> , 1410-1417				
DI	Robbins, L.S. et al., "Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function," <i>Cell</i> , <b>1993</b> , <i>72</i> , 827-834				
DJ	Rong, S. et al., "Met expression and sarcoma tumorigenicity," Cancer, 1993, 53(22), 5355-5360				
EXAMINER		DATE CONSIDERI	ED		

KECEIVED JUN 0 5 2002

ECH CENTER 1600/2900 Sheet 9 of 18

<b>Form PTO-1449</b>	Modified RADE
----------------------	---------------

Docket Norman **AREN-0320** 

Serial No. 10/083,168

List of Patent and Publications Cited by Applicant (Use several sheets if necessary) **Applicant** Chen W. Liaw et al.

U.S. Department of Commerce Patent and Trademark Office

Filing Date February 26, 2002 1646

Group

ОТНЕ	R DOCUMENTS (Including Author,			
DK	Samama, P. et al., "A mutation-induced activation state of the β2-adrenergic receptor," J. Biol. Chem., 1993, 268(7), 4625-4636			
DL	Sautel, M. et al., "Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor," Am. Soc. Pharm. Exp. Ther., 1996, 50, 285-292			
DM	Sawutz, D.G. et al., "Pharmacology and structure-activity relationships of the nonpeptide bradykinin receptor antagonist WIN 64338," <i>Can. J. Physiol. Pharmacol.</i> , <b>1995</b> , <i>73</i> , 805-811			
DN	Scheer, A. et al., "Constitutively active of receptor activation," J. Rec. Signal Ti	G protein-coupled receptors: potential mechanisms ransduct. Res., 1997, 17(1-3), 57-73		
DO	Scheer, A. et al., "The activation process of the $\alpha_{1B}$ -adrenergic receptor: Potential role of protonation and hydrophobicity of a highly conserved aspartate," <i>Proc. Natl. Acad. Sci. USA</i> , <b>1997</b> , <i>94</i> , 808-813			
DP	Schwinn, D.A. et al., "Cloning and pharmacological characterization of human Alpha-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues," J. Pharmacol., 1995, 272(1), 134-142			
DQ	Schild, L. et al., "A mutation in the epithelial sodium channel causing Liddle disease increases channel activity in the <i>Xenopus laevis</i> oocyte expression system," <i>Proc. Natl. Acad. Sci. USA</i> , <b>1995</b> , <i>92</i> , 5699-5703			
DR	Seeman, P. et al., "Dopamine receptor pharmacology," <i>Trends Pharmacol. Sci.</i> , <b>1994</b> , 15, 264-270			
DS	Seeman, P. et al., "Dopamine D4 receptors elevated in schizophrenia," <i>Nature</i> , 1993, 365, 441-445			
DT	Serradeil-Le Gale, C. et al., "Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V <sub>1a</sub> receptors," <i>J. Clin. Invest.</i> , <b>1993</b> , <i>92</i> , 224-231			
DU	Sharif, M. et al., "Malignant transformation by G protein-coupled hormone receptors," Mol. Cell. Endocrinology, 1994, 100, 115-119			
EXAMINER		DATE CONSIDERED		

COPY OF PAPERS ORIGINALLY FILED

1

7



RECEIVED

JUN 0 5 2002

GECH CENTER 1600/29006 18

#### Form PTO-1449 Modified

List of Patent and Publications Cited by Applicant (Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office

Dockets OF MARKS

Serial No. 10/083,168

Applicant

Chen W. Liaw et al.

Filing Date

Group

	at and Trademark Office	February 26, 2002	1646	
ОТНЕ	R DOCUMENTS (Including Author	r, Title, Date, Pertine	nt Pages, Etc.)	
DV	Showers, M.O. et al., "Activation of the erythropoietin receptor by the Friend spleen focus-forming virus gp55 glycoprotein induces constitutive protein tyrosine phosphorylation," <i>Blood</i> , <b>1992</b> , <i>80</i> (12), 3070-3078			
DW	Skinner, R.H. et al., "Direct measurer using scintillation proximity assay,"			
DX	Slamon, D.J. et al., "Human breast ca amplification of the HER-2/neu onco		_	
DY	Slamon, D. et al., "Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer," Science, 1989, 244, 707-712			
DZ	Solomon, Y. et al., "A highly sensitive adenylate cyclase assay," <i>Anal. Biochem.</i> , 1974, 58, 541-548			
EA	Spiegel, A.M., "Defects in G protein-coupled signal transduction in human disease," Ann. Rev. Physiol., 1995, 58, 143-170			
ЕВ	ter Laak, A. et al., "Modelling and mut binding site reveal different binding moderole in receptor stimulation," J. Computer	des for H <sub>1</sub> -agonists: Asp	<sup>16</sup> (TM3) has a constitutive	
EC	Tiberi, M. et al., "High agonist-indep dopamine D1B receptor subtype," J.			
ED	Tsujimura, T. et al., "Constitutive act cells caused by deletion of seven ami <b>1996</b> , <i>87(1)</i> , 273-283			
EE	Wang, Z. et al., "Constitutive μ opioi underlying narcotic tolerance and dep	-		
EF	Watowich, S.S. et al., "Homodimeriz erythropoietin receptor," <i>Proc. Natl.</i>			
EXAMINER		DATE CONSIDER	ED	

.

10000





JUN 0 5 2002

TECH CENTER 1600/2900 Sheet 11 of 18

Form	Modified	Docket No. AREN-0320	Serial No. 10/083,168	
	Patent and Publications Cited by Applicant veral sheets if necessary)	Applicant Chen W. Liaw et al.		
	repartment of Commerce t and Trademark Office	Filing Date February 26, 2002	Group 1646	
ОТНЕ	R DOCUMENTS (Including Author	r, Title, Date, Pertine	nt Pages, Etc.)	
EG	Weber-Nordt, R.M. et al., "Constitute lymphoid and myeloid leukemia cells lymphoma cell lines," <i>Blood</i> , <b>1996</b> , 8	s and in Epstein-Barr v	proteins in primary irus (EBV)-related	
ЕН	Webster, M.K. et al., "Constitutive act transmembrane point mutation found in	ivation of fibroblast grovachondroplasia," EMBC	wth factor receptor 3 by the 0 J., 1996, 15, 520-527	
EI	Xu, Y. et al., "Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines," <i>Proc. Natl. Acad. Sci. USA</i> , 1984, 81, 7308-7312			
EJ	Yamada, K. et al., "Substitution of the insulin receptor transmembrane domain with the <i>c-neu/erbB2</i> transmembrane domain constitutively activates the insulin receptor kinas in vitro," J. Biol. Chem., 1992, 267(18), 12452-12461			
EK	Zhang, S. et al., "Identification of Dy Receptor-Like Orphan Receptor," J.	morphins as Endogeno Biol. Chem., 1995, 270	us Ligands for an Opioid 0, 22772-22778	
EL	Zhen, Z. et al., "Structural and function of the HGF-receptor (Met)," Oncoger			
EM	Pauwles, P.J. et al., "Review: Amino Activation of G-Protein-Coupled Red 135			
EN	Shryock, J. et al., "Inverse Agonists a A1 Adenosine Receptors Stably Exp Molecular Pharmacalogy, 1998, 53,	ressed in Chinese Ham		
ЕО	Wenzel-Seifert, et al., "High Constitute Receptor", Journal of Biological Che			
EP	Forman, B.M. et al., "Androstane Mo Receptor CAR-β", <i>Nature</i> , <b>1998</b> , 395		Deactivate the Nuclear	
EQ	Seifert, R. et al., "different Effects of mediated Signaling, Jrl. of Biological			
EXAMINER		DATE CONSIDER	ED	

COPY OF PAPER. ORIGINALLY FILED

.....

AND SALES





	MAY 2 8 200	EEICE .	JUN 0 5 2002 CENTER 1600 Sheet 12 of 18
Form	Property Modified	Docket No. AREN-0320	Serial No. 10/083,168
(	Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Chen W. Liaw, et al	•
	epartment of Commerce t and Trademark Office	Filing Date February 26, 2002	Group <b>1646</b>
OTHE	R DOCUMENTS (Including Author	r, Title, Date, Pertine	nt Pages, Etc.)
ER	Abola, A.P., et al., "Omo sapiens chr sequence," AC026756 XP-00217591		
/ ES	Adams, M.D., et al., "CIT-HSP-2286 2286K19, genomic survey sequence, 1 page		
ET	Birren, B., et al., "Homo sapiens chro XP002175913, April 27, <b>2000</b> , 1-40	omosome 11, clone RP	11-589F4," AC027026,
EU	Birren, B., et al., "Homo sapiens clor XP002175781, October 18, 1999, 1-4		rdered pieces," AC011780,
EV	Birren, B., et al., "Homo sapiens clor December 1, 1999, 1-38	ne RP11-14N15," AC0	16468, XP002175784,
EW	Boyer, J.L., et al., "Molecular cloning as receptor," Am. Soc. For Pharmacology 6 928-934	nd expression of an avian & Experimental Therape	n G protein-coupled P2Y nutics, XP-002175907, 1997,
EX	Burton, J., et al., "Human DNA sequ XP002175911, April 16, <b>2000</b> , 1-39	ence from clone RP11-	163L4," A1161458,
EY	Burton, J., "Human DNA sequence fi XP002175785, January 7, 2000	rom clone RP11-15909	9," AL136106,
EZ	Collier, R., "DJ68ON, 3 (G-protein c Q9NTTO, XP002168498, January 10		ment)," Accession Nr.
FA	Doe Joint Genome Institute, "Homo complete sequence," AC008547, XP	=	

DATE CONSIDERED

**EXAMINER** 





JUN 0 5 2002

TECH CENTER 1600/2900 Sheet 13 of 18

Form	PTO-1449 Modified	Docket No. AREN-0320	Serial No. 10/083,168	
	f Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Chen W. Liaw, et al		
	Department of Commerce nt and Trademark Office	Filing Date February 26, 2002	Group 1646	
ОТН	ER DOCUMENTS (Including Author	r, Title, Date, Pertine	nt Pages, Etc.)	
FB	Doe Joint Genome Institute, "Homo scomplete sequence," AC008754, XP6			
FC	Doe Joint Genome Institute, "Sequencing of human chromosome 5," AC008728, XP002175776, August 4, 1999, 1-42			
FD	Gempscpue, "Drosophila melanogaster genome survey sequence TET3 end of BAC # BACRO8K10 of RPCI-98 library from drosophila melanogaster (fruit fly)," AL065769, XP00217590			
FE	Hattori, M., et al., "Homo sapiens 171, 539 genomic of 11q13," AP000808, XP002175780, December 3, 1999, 1-45			
FF	Heise, C.E., et al., "Characterization of the human cysteinyl leukotriene 2 receptor," <i>J. Biological Chemistry</i> , September 29, <b>2000</b> , <i>275</i> (39), 30531-30536			
FG	Kjelsberg, M.A., et al., "constitutive a amino acid substitutions at a single si 1992, 265(3), 1430-1433			
FH	Mahairas, G.G., et al., "Sequence-tag, mapping and scanning the human gen 96, 9739-9744	<del>-</del>		
FI	Marchese, A., et al., "Novel GPCRs a boundaries of physiology and pharma			
FJ	O'Dowd, B.F., et al., "Discovery of the Genomics, XP-000863786, 1998, 310		oupled receptor genes,"	
FK	Ohono, M., et al., "Homo spiens mRN complete cds," AB038237, XP002175		* '	
FL	Stadel, J.M., et al., "Orphan G protein pioneer drug discovery," <i>TiPS</i> , Nover		• • • • •	
EXAMINER		DATE CONSIDER	ED	

COPY OF PAPERS

4

, Y







JUN 0 5 2002 TECH CENTER 1600/2900

Sheet 14 of 18

Form	1449 Modified	Docket No. AREN-0320	Serial No. 10/083,168
	f Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Chen W. Liaw, et al	
	Department of Commerce and Trademark Office	Filing Date February 26, 2002	Group 1646
ОТНЕ	ER DOCUMENTS (Including Author	r, Title, Date, Pertine	nt Pages, Etc.)
FM	Stone, N., et al., "Homo sapiens chor XP002175914, April 23, 1999, 1-52	nosome 4, 16 unordere	d pieces," AC007104,
FN	Wallis, J., "Human DNA sequence from clone RP5-1160K1," AL355310, XP002175782, May 5, <b>2000</b> , 1-39		
FO	Waterson, R.H., "homo sapiens chromosome 2 clone RP11-510c1," AC010984, XP002175915, September 29, 1999, 1-50		
FP	Weinshank, R.H., "5-hydroxytryptam AC 008892, XP002175948, July 15,		IB) (serotonin receptor),"
FQ	Zhao, S., et al., "Use of BAC end seq map building," AQ532303, XP00217	uences from library RF 5779, May 18, <b>1999</b> , 1	PCI-11 for sequence-ready page
FR	PCT International Search Report date	d September 19, 2001	
FS	Watson, S. et al., "The G-Protein linked receptor facts book", <i>Academic Press</i> , 2-6, 162-169		
FT	Rudinger, J. et al., <i>Peptide Hormones</i> 1-7	, J.A. Parsons, Unovers	sity Park Press, Baltimore,
EXAMINER		DATE CONSIDERE	CD

\* 3

Sand Later

COPY OF PAPERS



## RECEIVED JUN 0 5 200% f 18

EXAM	INER		DATE CONSIDERE	ED	
	GB	Scheer, A., et al., "Constitutively actimechanisms of receptor activation," J XP-000867531, 17(1-3), 57-73	ve G protein-coupled re I. Receptor & Signal Tr	eceptors: potential ransduction Res., 1997,	
	GA	Reppert, S.M., et al., "Cloning of a m <i>FEBS Letts.</i> , <b>1996</b> , XP-002145161, 2	Reppert, S.M., et al., "Cloning of a melatonin-related receptor from human pituitary," <i>FEBS Letts.</i> , <b>1996</b> , XP-002145161, 219-2254		
	FZ	Noda, K., et al., "The active state of tangiotensin II induction," Biochem., 1	he AT <sub>1</sub> angiotensin rec 1996, XP-002145163, .	eptor is generated by 35, 16435-16442	
	FY	Kyaw, H., et al., "Cloning, characteri mouse T-cell death-associated gene," 17(6), 493-500	zation, and mapping of DNA and Cell Biology	f human homolog of $\nu$ , <b>1998</b> , XP000929737,	
	FX	Koike, G., et al., "Human type 2 angiotensin II receptor gene: cloned, mapped to the X chromosome, and its mRNA is expressed in the human lung," <i>Biochem. And Biophy. Res. Comm.</i> , <b>1994</b> , XP-002145166, <i>203(3)</i> , 1842-1850			
	FW	Groblewski, T., et al., "Mutation of Asn <sup>111</sup> in the third transmembrane domain of the AT <sub>1a</sub> angiotensin II receptor induces its constitutive activation," J. Biol. Chem., 1997 XP-002145162, 272(3), 1822-1826			
	FV	Gantz, I., et al., "Molecular cloning, melanocortin receptor," J. Biol. Chem.	expression, and gene long, <b>1993</b> , XP-00205198	ocalization of a fourth 33, 268(20), 15174-15178	
	FU	Bergsma, D.J., et al., "Cloning and or receptor," Biochem. & Biophy. Res.			
	ОТН	ER DOCUMENTS (Including Autho	r, Title, Date, Pertine	nt Pages, Etc.)	
		Department of Commerce nt and Trademark Office	Filing Date October 13, 1998	Group 1646	
	•	Cited by Applicant everal sheets if necessary)	Applicant Liaw, et al.		
	Lists	of Patent and Publications	AREN-0040	09/170,496	
	Forh	BEOM 449 Modified BADE	Docket No.	Serial Fig. 1ER 1600/2900	

COPY OF PAPERS ORIGINALLY FILED

-

1

AND T

an and the latter



OTPE CONTRACTOR

## RECEIVED

JUN 0 5 2002

TECH CENTER 1600/2900 Sheet 16 of 18

## Form PTO-14 Modified

List of Patent and Publications Cited by Applicant (Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office

Becket No.
<b>AREN-0320</b>

Serial No. 10/083,168

Applicant

Chen W. Liaw, et al.

Eilinn	Data
Filing	Date

Group

February 26, 2002

1646

#### **U. S. PATENT DOCUMENTS**

	Document No.	Date	Name	Class	Subclass
GC	5,861,309	01/19/99	Bard, et al.	135	325
GD	5,891,720	04/06/99	Moore, et al.	435	325
GE	5,955,308	09/21/99	Bergsma, et al.	435	69.1
	GD	No. GC 5,861,309 GD 5,891,720	No.       Date         GC       5,861,309       01/19/99         GD       5,891,720       04/06/99	No.         Date         Name           GC         5,861,309         01/19/99         Bard, et al.           GD         5,891,720         04/06/99         Moore, et al.	No.         Date         Name         Class           GC         5,861,309         01/19/99         Bard, et al.         135           GD         5,891,720         04/06/99         Moore, et al.         435

#### FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES NO
	GF	WO 96/05302	02/22/96	PCT	
	GG	WO 97/21731	06/19/97	PCT	
	GH	WO 98/29439	07/09/98	PCT	
	GI	WO 98/46620	10/22/98	PCT	
	GJ	WO 98/56820	12/17/98	PCT	
	GK	WO 99/06552	02/11/99	PCT	
	GL	WO 99/32519	07/01/99	PCT	
	GM	WO 99/48921	09/30/99	PCT	
	GN	WO 00/14229	03/16/00	PCT	X (abstract)
	GO	WO 00/22131	04/20/00	PCT	
	GP	WO 00/49046	08/24/00	PCT	X (abstract)
	GQ	WO 01/07606 A1	02/01/01	PCT	
	GR	WO 01/09184 A1	02/08/01	PCT	
	GS	WO 01/12673 A1	02/22/01	PCT	
EXAMINE	R			DATE CONSI	DERED

COPY OF PAPERS

...

1000

7

78.0

Œ.



JUN 0 5 2002

TECH CENTER 1600/8999

#### Form PTO 49 Modified

List of Patent and Publications Cited by Applicant (Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office

ket No. AREN-0320 Serial No. 10/083,168

**Applicant** 

Chen W. Liaw, et al.

Filing Date

Group 1646

February 26, 2002

#### FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country		nslation NO
	GT	WO 01/14577 A1	03/01/01	PCT		
	GU	WO 01/16159 A1	03/08/01	PCT		
	GV	WO 01/31014 A2	05/03/01	PCT		
	GW	WO 01/36471 A2	05/25/01	PCT		
	GX	0 612 845 A2	08/31/94	ЕРО		
	GY	0 878 542 A2	11/18/98	EPO		
	GZ	0 892 051 A2	01/20/99	ЕРО		
	НА	1 090 989 A1	04/11/01	ЕРО		
	нв	1 094 076 A1	04/25/01	ЕРО		
	нс	8-245697	09/24/99	Japan		Х
	HD	11-32770	02/09/99	Japan		Х
	HE	11-98988	09/13/99	Japan	X (abstract)	
EXAMINE	₹			DATE CONSII	DERED	!

3

在北京 大有



JUN 0 5 2002

TECH CENTER +608/29018

#### **P**ódified

List of Patent and Publications Cited by Applicant (Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office

ket No. AREN-0320 Serial No. 10/083,168

**Applicant** 

Chen W. Liaw et al.

Filing Date February 26, 2002

Group 1646

#### **U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
	HF	5,514,578	05/07/96	Hogness et al.	435	240.2
	HG	5,532,157	07/02/96	Fink	435	240.2
	НН	5,573,944	11/12/96	Kirschner et al.	435	252.3
	HI	5,639,616	06/17/97	Liao et al.	435	7.1
	HJ	5,750,353	05/12/98	Kopin et al.	435	7.21
-						

#### FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES NO	
	HK	WO 97/11159	09/20/96	PCT	X	_
	HL	WO 97/21731 A	06/19/97	PCT	X	
	НМ	WO 98/38217 A	09/03/98	PCT	X	
	HN	WO 98/46995	10/22/98	PCT	X	_
	но	WO 99/52927	10/21/99	PCT	X	_
	HP	WO 98/00552	01/08/98	PCT	X	1
	НQ	WO 98/34948	08/13/98	PCT	X	$\dashv$
	HR	WO/99 24569	05/20/99	Japan	X	$\dashv$
	HS	2,135,253	08/05/96	Canada	X	$\forall$
EXAMINER			DATE CONSIDERED			

. . .